Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea (EUIPO) reabre los Bonos 1 (IP Scan y IP Scan Enforcement), 2 (Marcas y Diseños) y 3 (patentes) del SME Fund para pymes y emprendedores, que pueden solicitar las ayudas desde el 20 de octubre de 2025.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
143
resultados
Última actualización
15/11/2025 [07:10:00]
Resumen de: US2025345512A1
Provided are a method, system, and computer-readable medium for optimizing glycemic control of a diabetic subject having Type 1 diabetes through co-administration of sodium-glucose cotransporter inhibitors (SGLTi) and insulin. Such co-administration can be effected by, for example, regulating one or more administration reactions in view of analyses of continuous glucose monitoring (CGM) data that can be indicative of at least the potential for one or more glycemic events including hypoglycemia and hyperglycemia. The aforementioned regulation can occur according to a balancing of insulin infusion and provisioning of SGLTi so as to avoid the occurrence of either of such events while, at the same time, not promoting an instance of diabetic ketoacidosis (DKA).
Resumen de: US2025344973A1
A method for optional external calibration of a calibration-free glucose sensor uses values of measured working electrode current (Isig) and EIS data to calculate a final sensor glucose (SG) value. Counter electrode voltage (Vcntr) may also be used as an input. Raw Isig and Vcntr values may be preprocessed, and low-pass filtering, averaging, and/or feature generation may be applied. SG values may be generated using one or more models for predicting SG calculations. When an external blood glucose (BG) value is available, the BG value may also be used in calculating the SG values. A SG variance estimate may be calculated for each predicted SG value and modulated, with the modulated SG values then fused to generate a fused SG. A Kalman filter, as well as error detection logic, may be applied to the fused SG value to obtain a final SG, which is then displayed to the user.
Resumen de: AU2025248709A1
Described herein are doses and dosing regimens comprising determining and administering doses of long-acting insulin receptor agonists suitable for once-weekly dosing, such as Weekly Basal Insulin-Fc (BIF). Described herein are doses and dosing regimens comprising determining and administering doses of long-acting insulin receptor agonists suitable for once-weekly dosing, such as Weekly Basal Insulin-Fc (BIF). ct c t
Resumen de: AU2024252324A1
A method of therapy escalation for patients with diabetes includes receiving glucose data of a user from an in vivo glucose monitoring device, receiving first therapy information of a first therapy, wherein the first therapy includes basal insulin, calculating one or more glucose metrics based on the received glucose data, titrating a dose of the basal insulin based on the one or more glucose metrics, and determining overbasalization based on one or more of the glucose data and the first therapy information. Advantageously the system can regularly monitor glucose control of a user, detect overbasalization, provide frequent therapy intervention and adjustment, decrease a duration of intervention, and increase user adherence, outcomes, and satisfaction.
Resumen de: US2025344967A1
Glucose measurement and glucose-impacting event prediction using a stack of machine learning models is described. A CGM platform includes stacked machine learning models, such that an output generated by one of the machine learning models can be provided as input to another one of the machine learning models. The multiple machine learning models include at least one model trained to generate a glucose measurement prediction and another model trained to generate an event prediction, for an upcoming time interval. Each of the stacked machine learning models is configured to generate its respective output when provided as input at least one of glucose measurements provided by a CGM system worn by the user or additional data describing user behavior or other aspects that impact a person's glucose in the future. Predictions may then be output, such as via communication and/or display of a notification about the corresponding prediction.
Resumen de: US2025344969A1
A noninvasive system and method estimate hemoglobin A1c, glucose, lipids, and other blood analytes without requiring a blood sample. The portable device uses diffuse reflectance spectroscopy and optical sensing across various wavelengths to collect data from the user's skin, interstitial fluid, saliva, sweat, tear fluid, or exhaled air. Machine learning algorithms analyze the optical data to estimate blood analyte levels, which are displayed on the device or synced with a software application. The system securely transmits data to the user's electronic health record for integration and remote monitoring. The invention encompasses FDA-approved, CE-marked, and non-FDA-approved devices, including key components, digital health features, and various medical applications.
Resumen de: EP4647772A2
Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.
Resumen de: AU2025252653A1
Abstract The present disclosure relates to a sterile medical product for parenteral nutrition comprising a polymeric container having at least a first and a second chamber which are sep- arated by a non-permanent peel seal, wherein the first chamber contains a composition of amino acids and optional- ly electrolytes, and wherein the second chamber contains a dextrose solution, and wherein the product is characterized by a high protein (nitrogen) content per volume. The recon- stituted solution is configured to be administered periph- erally or centrally for the treatment of patients suffering from malnutrition and/or having a need for increased uptake of amino acids. Abstract The present disclosure relates to a sterile medical product for parenteral nutrition comprising a polymeric container having at least a first and a second chamber which are sep- arated by a non-permanent peel seal, wherein the first chamber contains a composition of amino acids and optional- ly electrolytes, and wherein the second chamber contains a dextrose solution, and wherein the product is characterized by a high protein (nitrogen) content per volume. The recon- stituted solution is configured to be administered periph- erally or centrally for the treatment of patients suffering from malnutrition and/or having a need for increased uptake of amino acids. ct b s t r a c t c t h e p r e s e n t d i s c l o s u r e r e l a t e s t o a s t e r i l e m e d i c a l p r o d u c t f o r p a r e n t e r a l n
Resumen de: US2025341624A1
A system for millimeter RADAR object recognition and classification using sub-band frequency interference and resonance effects from primary targets signals and reflected signals from secondary target preferably in the form of Wideband Chaos Generating Material (WCGM) objects, preferably detecting frequency dependent absorbing material, frequency dependent resonance effects from the second and primary target objects, frequency signal resonance effects caused by water molecule dipole effects in different sugar solutions, impedance of material, shape of metamaterial, and interference effects due to combination of signal sources resulting in a wider range of transmitter and scanning frequency band for RADAR based interrogation of target objects. The RADAR system makes opportunistic use of traditionally seen problematic interference signals, as extra signal sources providing extended range and frequency bandwidth for frequency-based interrogation of target object signatures in a frequency-intensity plane, a frequency-polarization plane, and a frequency-phase shift plane for doppler effects.
Resumen de: US2025342932A1
Dose guidance systems and methods for titrating medication doses are described. The dose guidance system may receive glucose data from a continuous glucose monitor and may receive medication data related to medication administered by the user. The dose guidance system may initialize dose guidance parameters, recommend medication doses, titrate medication doses, and provide alerts based on the glucose data and medication data.
Resumen de: WO2025231209A1
A computing system, a computer implemented method, and a wearable computing device to predict insulin resistance in a wearer of the wearable computing device without requiring additional invasive testing other than test data that may already be available, although not required, is provided. For instance, a machine-learned model is trained to predict insulin resistance in the wearer of the wearable computing device based at least in part on non-invasive biometric data associated with the wearer. Then, one or more non-transitory computer-readable media cause the computing system to perform operations via one or more processors. The operations include receiving the non-invasive biometric data from one or more sensors associated with the wearable computing device; and implementing the machine-learned model to determine if the non-invasive biometric data associated with the wearer is indicative of insulin resistance.
Resumen de: US2025339612A1
The present disclosure relates to a self-lubricating cannula for use in delivering a fluid medication to a subcutaneous site. The self-lubricating cannula comprises polyether block polyamide and an additive configured to facilitate the manufacture of a tipped self-lubricating cannula. The present disclosure also provides a method of making a self-lubricating cannula and a method of administering insulin using a self-lubricating cannula.
Resumen de: US2025339033A1
Near Infrared Spectroscopy is employed to non-invasively detect blood glucose concentrations, in a multi-sensing detection device. A multi-layered artificial neural network is used to assess these relationships of non-linear interference from human tissue, as well as differences among individuals, and accurately estimate blood glucose levels. Diffuse reflectance spectrum from the palm at six different wavelengths analyzed with a neural network, results in a correlation coefficient as high as 0.9216 when compared to a standard electrochemical glucose analysis test.
Resumen de: US2025339060A1
Devices, systems and methods for blood glucose monitoring. The device includes a light emitter, configured to emit light signals; a light receiver, configured to receive the reflected light signal; a controller, configured to operatively connect with the light emitter and the light receiver; and an enclosure. The light signal comprises a first light signal having a first wavelength of about 940 nm, a second light signal having a second wavelength of about 1350 nm, and/or a third light signal having a third wavelength of about 1500 nm, wherein the controller comprises an operating module, and further comprises or operatively connects with a data processing system comprising a machine learning module that analyzes the data signal to generate an output data. The devices, systems and methods are non-invasive and monitor blood glucose levels in real time with high accuracy.
Resumen de: US2025339617A1
Exemplary embodiments may modify the cost function parameters based on current and projected mean outcomes in blood glucose level control performance. The exemplary embodiments may modify the weight coefficient R for the insulin cost so that the value of R is not fixed and is not based solely on clinical determined values. Exemplary embodiments may also adjust the cost function to address persistent low-level blood glucose level excursions for users. The exemplary embodiments may reduce the penalty of the insulin cost by the sum of the converted insulin cost of the glucose excursions above target for a period divided by a number of cycles of average insulin action time. The AID system reduces the insulin cost by the lack of insulin in previous cycles.
Resumen de: US2025339611A1
The present disclosure relates to the use of a PFAS-free cannula in delivering a fluid medication, such as insulin, to a subcutaneous site. The cannula comprises polycarbonate polyurethane polysiloxane (PC-PU-PS), wherein the cannula is configured for subcutaneous insertion into the tissue of the individual in need thereof. The disclosure includes methods for administering insulin using the cannula and infusion devices comprising the cannula.
Resumen de: US2025339064A1
A diagnostic Electrochemical Impedance Spectroscopy (EIS) procedure is applied to measure values of impedance-related parameters for one or more sensing electrodes. The parameters may include real impedance, imaginary impedance, impedance magnitude, and/or phase angle. The measured values of the impedance-related parameters are then used in performing sensor diagnostics, calculating a highly-reliable fused sensor glucose value based on signals from a plurality of redundant sensing electrodes, calibrating sensors, detecting interferents within close proximity of one or more sensing electrodes, and testing surface area characteristics of electroplated electrodes. Advantageously, impedance-related parameters can be defined that are substantially glucose-independent over specific ranges of frequencies. An Application Specific Integrated Circuit (ASIC) enables implementation of the EIS-based diagnostics, fusion algorithms, and other processes based on measurement of EIS-based parameters.
Resumen de: US2025339338A1
A blood storage container along with an aqueous composition for the storage of packed red blood cells is described. In a preferred embodiment, the container is not made of DEHP plasticizer. In some embodiments, the container is made from a polymeric material and a non-DEHP plasticizer. In some embodiments, the aqueous composition is made of about 1 to about 3 mM adenine, about 20 to about 115 mM dextrose, about 15 to about 60 unmetabolizable membrane-protectant sugar, about 20 to about 30 mM sodium bicarbonate, and about 4 to about 20 mM disodium phosphate. In a most preferred embodiment, the DEHP-lacking container is made from a PVC polymeric material and a DINCH plasticizer and the aqueous composition is made of about 2 mM adenine, about 80 mM dextrose, 55 mM unmetabolizable membrane-protectant sugar, about 26 mM sodium bicarbonate, and about 12 mM disodium phosphate.
Resumen de: US2025339618A1
A system for monitoring autonomic nervous system (ANS) function in a subject includes at least one sensor configured to acquire a first physiological signal related to heart activity of the subject, one or more additional sensors configured to acquire one or more physiological signals, a processing unit configured to receive, process and analyze the first and additional physiological signals to monitor/detect, in real time, at least one of an autonomic nervous system dysfunction and a change in a physiological state of the subject and determine an output condition based on the detection, and an output mechanism configured to perform, based on the output condition, generating an alert, initiating a treatment, and/or storing data. At least one of the additional sensors is a blood glucose sensor, a respiration sensor, a sudomotor activity sensor, a pulse wave sensor, an electroencephalography (EEG) sensor, an electromyography (EMG) sensor or a motion sensor.
Resumen de: AU2023415722A1
Certain aspects of the present disclosure relate to a monitoring system comprising a continuous analyte sensor configured to generate analyte measurements associated with analyte levels of a patient, and a sensor electronics module coupled to the continuous analyte sensor and configured to receive and process the analyte measurements.
Resumen de: EP4643911A1
The present disclosure relates to the use of a PFAS-free cannula in delivering a fluid medication, such as insulin, to a subcutaneous site. The cannula comprises polycarbonate polyurethane polysiloxane (PC-PU-PS), wherein the cannula is configured for subcutaneous insertion into the tissue of the individual in need thereof. The disclosure includes methods for administering insulin using the cannula and infusion devices comprising the cannula.
Resumen de: EP4643777A1
Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.
Resumen de: EP4643910A1
The present disclosure relates to a self-lubricating cannula for use in delivering a fluid medication to a subcutaneous site. The self-lubricating cannula comprises polyether block polyamide and an additive configured to facilitate the manufacture of a tipped self-lubricating cannula. The present disclosure also provides a method of making a self-lubricating cannula and a method of administering insulin using a self-lubricating cannula.
Resumen de: EP4643774A1
Provided is an implant apparatus for a continuous glucose monitor. The implant apparatus includes a housing assembly and a driving assembly disposed in the housing assembly. The housing assembly includes an outer housing. The outer housing has an opening at an end of the outer housing. The driving assembly has a locked state in which the driving assembly is fixed relative to the outer housing and a triggered state in which the driving assembly is movable towards the opening. The implant apparatus further includes a trigger. The outer housing includes a guiding channel located at a side wall of the outer housing and extending towards the opening. The trigger is movable along the guiding channel towards the opening and has a first position and a second position relative to the outer housing, to enable the driving assembly to switch from the locked state to the triggered state. A triggering direction of the trigger is oriented towards the opening, while a direction of a force applied by fingers of a user when the user holds the outer housing is oriented inwards in a radial direction of the outer housing. Force application directions of the two actions are perpendicular to each other. As a result, a probability of the user accidentally triggering the trigger when holding the outer housing is reduced, which reduces a risk of accidental triggering of the implant apparatus, improving use experience.
Nº publicación: IL323729A 01/11/2025
Solicitante:
BIGFOOT BIOMEDICAL INC [US]
OLSON II BYRON PAUL [US]
JACOBY JEANNE M [US]
CLEMENTE MATTHEW [US]
BIGFOOT BIOMEDICAL INC,
OLSON II Byron Paul,
JACOBY Jeanne M,
CLEMENTE Matthew
Resumen de: WO2024211880A2
A method of therapy escalation for patients with diabetes includes receiving glucose data of a user from an in vivo glucose monitoring device, receiving first therapy information of a first therapy, wherein the first therapy includes basal insulin, calculating one or more glucose metrics based on the received glucose data, titrating a dose of the basal insulin based on the one or more glucose metrics, and determining overbasalization based on one or more of the glucose data and the first therapy information. Advantageously the system can regularly monitor glucose control of a user, detect overbasalization, provide frequent therapy intervention and adjustment, decrease a duration of intervention, and increase user adherence, outcomes, and satisfaction.
BOPI
Sede Electrónica
